Crinetics Pharmaceuticals Provides Update on CRN04777 Program
28 nov. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin...
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at...
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 nov. 2022 16h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
13 oct. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 oct. 2022 16h57 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
06 oct. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted...
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
03 oct. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 sept. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual...